Peptinovo Biopharma

Executive Summary

Peptinovo Biopharma is a preclinical-stage biotechnology company based in San Diego, specializing in drug delivery. Its proprietary PALM™ carrier platform is designed to enhance the delivery and efficacy of chemotherapeutic agents. The lead candidate, PNB-281, combines the PALM carrier with paclitaxel, a widely used chemotherapy drug, and is currently completing pre-IND enabling studies. The company has also developed four additional chemotherapy drugs using the same platform, ready to enter pre-IND testing. This pipeline positions Peptinovo to address key limitations of current chemotherapy, such as poor bioavailability and systemic toxicity, potentially improving patient outcomes. As a private company founded in 2018, Peptinovo is at an early stage but has a clear roadmap to clinical development. The platform's versatility across multiple drugs could provide a competitive advantage, though validation through regulatory filings and clinical data is still needed. Success will depend on advancing PNB-281 to the clinic and demonstrating safety and efficacy.

Upcoming Catalysts (preview)

• Q4 2026Completion of pre-IND enabling studies for PNB-28170% success
• H1 2027IND filing for PNB-28150% success
• 2027Initiation of pre-IND studies for pipeline candidates60% success